Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Exp Ther Med
2015 Jun 01;96:2151-2154. doi: 10.3892/etm.2015.2372.
Show Gene links
Show Anatomy links
Association between EML4-ALK fusion gene and thymidylate synthase mRNA expression in non-small cell lung cancer tissues.
Xu CW
,
Wang G
,
Wang WL
,
Gao WB
,
Han CJ
,
Gao JS
,
Zhang LY
,
Li Y
,
Wang L
,
Zhang YP
,
Tian YW
,
Qi DD
.
???displayArticle.abstract???
This study aimed to investigate the association of the mRNA expression of the echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion gene with that of thymidylate synthase (TYMS) in non-small cell lung cancer (NSCLC) tissues. Quantitative polymerase chain reaction was used to detect the expression of EML4-ALK fusion gene and TYMS mRNA in 257 cases of NSCLC. The positive rate of EML4-ALK fusion gene was 4.28% in the NSCLC tissues (11/257), and was higher in nonsmokers than in smokers (P<0.05); TYMS mRNA expression was detected in 63.42% (163/257) of cases. An association of the EML4-ALK fusion gene with TYMS expression was detected; a low expression level of TYMS mRNA was observed more frequently when the EML4-ALK fusion gene was present than when it was not detected (P<0.05). In conclusion, patients positive for the EML4-ALK fusion gene in NSCLC tissues are likely to have a low expression level of TYMS, and may benefit from the first-line chemotherapy drug pemetrexed.
Choi,
EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.
2010, Pubmed,
Echinobase
Choi,
EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.
2010,
Pubmed
,
Echinobase
Chu,
Thymidylate synthase protein and p53 mRNA form an in vivo ribonucleoprotein complex.
1999,
Pubmed
Diasio,
The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil.
2000,
Pubmed
Fukushima,
Population study of expression of thymidylate synthase and dihydropyrimidine dehydrogenase in patients with solid tumors.
2003,
Pubmed
Gomez,
A phase II trial of pemetrexed in advanced breast cancer: clinical response and association with molecular target expression.
2006,
Pubmed
Horn,
EML4-ALK: honing in on a new target in non-small-cell lung cancer.
2009,
Pubmed
Inamura,
EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers.
2008,
Pubmed
,
Echinobase
Jemal,
Global cancer statistics.
2011,
Pubmed
Kawakami,
Prognostic role of thymidylate synthase polymorphisms in gastric cancer patients treated with surgery and adjuvant chemotherapy.
2005,
Pubmed
Kwak,
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
2010,
Pubmed
Martelli,
EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues.
2009,
Pubmed
,
Echinobase
Perner,
EML4-ALK fusion lung cancer: a rare acquired event.
2008,
Pubmed
Righi,
Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy.
2010,
Pubmed
Rikova,
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.
2007,
Pubmed
Sasaki,
The biology and treatment of EML4-ALK non-small cell lung cancer.
2010,
Pubmed
,
Echinobase
Shaw,
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.
2009,
Pubmed
Shaw,
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
2013,
Pubmed
Sher,
Small cell lung cancer.
2008,
Pubmed
Soda,
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
2007,
Pubmed
,
Echinobase
Sun,
Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.
2010,
Pubmed
Wong,
The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.
2009,
Pubmed
,
Echinobase
Zhang,
Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression.
2010,
Pubmed
